General Information of Drug (ID: DMBWY8V)

Drug Name
Omega-6-FA Drug Info
Synonyms Fatty Acids, Omega-6; Omega-6 Fatty Acids; Omega-6 Polyunsaturates; N-6 Fatty Acids; SCHEMBL17080398
Cross-matching ID
PubChem CID
56842208
TTD Drug ID
DMBWY8V
INTEDE Drug ID
DR1195

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DME
Drug Status:
Approved Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [2]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [3]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [4]
Epanova DMHEAGL Hypertriglyceridemia 5C80.1 Approved [5]
Gamma-Homolinolenic acid DMSXKYG Malnutrition 5B50-5B71 Approved [4]
Gamolenic acid DMQN30Z Allergy 4A80-4A85 Approved [4]
Arachidonic Acid DMUOQZD Discovery agent N.A. Investigative [6]
alpha-linolenic acid DMY64HE Discovery agent N.A. Investigative [4]
Eicosadienoic acid DMVJK9W N. A. N. A. Investigative [4]
Icosapentum DMF1CM7 N. A. N. A. Investigative [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Arachidonate 5-lipoxygenase (ALOX5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epanova DMHEAGL Hypertriglyceridemia 5C80.1 Approved [7]
Arachidonic Acid DMUOQZD Discovery agent N.A. Investigative [8]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) DE492CE PGH2_HUMAN Substrate [1]
Arachidonate 5-lipoxygenase (ALOX5) DE87OZS LOX5_HUMAN Substrate [1]
Fatty acid desaturase 1 (FADS1) DE05S8C FADS1_HUMAN Substrate [1]
Fatty acid desaturase 2 (FADS2) DEDI4B8 FADS2_HUMAN Substrate [1]

References

1 Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
2 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
3 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
4 Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
5 Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63.
6 PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenet Genomics. 2011 Sep;21(9):607-13.
7 Omega-3 fatty acids and inflammatory processes. Nutrients. 2010 Mar;2(3):355-74.
8 A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors. Eur J Pharmacol. 2008 Apr 14;584(1):166-74.